Investor Presentation Q1-Q3 2020

4 Investor presentation First nine months of 2020 Strategic aspirations 2025 - Highlights first nine months of 2020 Purpose and sustainability Adding value to society: Launch of new social responsibility strategy 'Defeat Diabetes' • Expansion of US affordability offerings Lowered ceiling price of human insulin in 76 countries Environment: 100% renewable power across all production sites Launch of supplier target aiming at 100% renewable power by 2030 ピ • Diabetes sales increased by 8%: Value market share leadership expanded by 0.8%- points to 29.2% Sales of GLP-1 increased by 29% driven by continued performance of OzempicⓇ Obesity sales increased by 6% to DKK 4.2 billion Biopharm sales increased by 4% driven by IO Commercial execution therapeutic focus Innovation and Financials . • . . • Diabetes: Insulin icodec phase 2 trial successfully completed RybelsusⓇ approved in the EU, the UK and Japan Obesity: Sema 2.4 mg obesity phase 3 programme and AM833 + sema 2.4 mg phase 1 trial successfully completed Biopharm: Concizumab phase 3 reinitiated Other serious chronic disease: Successful completion of phase 2 trials for zilti and semaglutide in NASH Sales increased by 7% to DKK 94.8 billion • • 12% sales growth in IO 2% sales growth in NAO, with 47% of US sales transformed to products launched since 2015 Operating profit increased by 7% to DKK 42.9 billion Free cash flow increased by 27% to DKK 41.6 billion and DKK 31 billion returned to shareholders The strategic aspirations are objectives that Novo Nordisk intends to work towards and are not a projection of Novo Nordisk's financial outlook or expected growth Note: Unless otherwise specified growth rates are at constant exchange rates IO: International Operations; NAO: North America Operations; Sema: Semaglutide; NASH: Non-alcoholic steatohepatitis Novo NordiskⓇ

View entire presentation